The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies
Open accessAbstract
Cancer immunotherapy by immune checkpoint blockade has proven its great potential by saving the lives of a proportion of late stage patients with immunogenic tumor types. However, even in these sensitive tumor types, the majority of patients do not sufficiently respond to the therapy. Furthermore, other tumor types, including glioblastoma, remain largely refractory. The glioblastoma immune microenvironment is recognized as highly immunosuppressive, posing a major hurdle for inducing immune-mediated destruction of cancer cells. Scattered information is available about the presence and activity of immunosuppressive or immunostimulatory cell types in glioblastoma tumors, including tumor-associated macrophages, tumor-infiltrating dendritic cells and regulatory T cells. These cell types are heterogeneous at the level of ontogeny, spatial distribution and functionality within the tumor immune compartment, providing insight in the complex cellular and molecular interplay that determines the immune refractory state in glioblastoma. This knowledge may also yield next generation molecular targets for therapeutic intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
Patel, A. P., Tirosh, I., Trombetta, J. J., Shalek, A. K., Gillespie, S. M., Wakimoto, H., Cahill, D. P., Nahed, B. V., Curry, W. T., Martuza, R. L., et al. (2014) · Science · doi:10.1126/science.1254257 · Cited by 5,063
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma
Neftel, C., Laffy, J., Filbin, M. G., Hara, T., Shore, M. E., Rahme, G. J., Richman, A. R., Silverbush, D., Shaw, M. L., Hebert, C. M., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.024 · Cited by 2,873
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Pyonteck, S. M., Akkari, L., Schuhmacher, A. J., Bowman, R. L., Sevenich, L., Quail, D. F., Olson, O. C., Quick, M. L., Huse, J. T., Teijeiro, V., et al. (2013) · Nature Medicine · doi:10.1038/nm.3337 · Cited by 2,463
Ceccarelli, M., Barthel, F. P., Malta, T. M., Sabedot, T. S., Salama, S. R., Murray, B. A., Morozova, O., Newton, Y., Radenbaugh, A., Pagnotta, S. M., et al. (2016) · Cell · doi:10.1016/j.cell.2015.12.028 · Cited by 2,189
Landscape of Infiltrating T Cells in Liver Cancer Revealed by Single-Cell Sequencing
Zheng, C., Zheng, L., Yoo, J.-K., Guo, H., Zhang, Y., Guo, X., Kang, B., Hu, R., Huang, J. Y., Zhang, Q., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.035 · Cited by 2,152
Wang, Q., Hu, B., Hu, X., Kim, H., Squatrito, M., Scarpace, L., deCarvalho, A. C., Lyu, S., Li, P., Li, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.003 · Cited by 1,995
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857 · cited 4×
“mokines, such as Flt3L, CCL5 and XCL1 (Böttcher et al., 2018; Barry et al., 2018).”
BackgroundInfluentialIntratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
Sottoriva, A., Spiteri, I., Piccirillo, S. G. M., Touloumis, A., Collins, V. P., Marioni, J. C., Curtis, C., Watts, C., & Tavaré, S. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219747110 · Cited by 1,737
Cancer stem cells in glioblastoma
Lathia, J. D., Mack, S. C., Mulkearns-Hubert, E. E., Valentim, C. L. L., & Rich, J. N. (2015) · Genes & Development · doi:10.1101/gad.261982.115 · Cited by 1,520
Zilionis, R., Engblom, C., Pfirschke, C., Savova, V., Zemmour, D., Saatcioglu, H. D., Krishnan, I., Maroni, G., Meyerovitz, C. V., Kerwin, C. M., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.009 · Cited by 1,475
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432
The cellular and molecular origin of tumor-associated macrophages
Franklin, R. A., Liao, W., Sarkar, A., Kim, M. V., Bivona, M. R., Liu, K., Pamer, E. G., & Li, M. O. (2014) · Science · doi:10.1126/science.1252510 · Cited by 1,393
Cloughesy, T. F., Mochizuki, A. Y., Orpilla, J. R., Hugo, W., Lee, A. H., Davidson, T. B., Wang, A. C., Ellingson, B. M., Rytlewski, J. A., Sanders, C. M., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0337-7 · Cited by 1,382
Movahedi, K., Laoui, D., Gysemans, C., Baeten, M., Stangé, G., Van den Bossche, J., Mack, M., Pipeleers, D., In't Veld, P., De Baetselier, P., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4672 · Cited by 1,239
Self-citationMovahedi, K., Guilliams, M., Van den Bossche, J., Van den Bergh, R., Gysemans, C., Beschin, A., De Baetselier, P., & Van Ginderachter, J. A. (2008) · Blood · doi:10.1182/blood-2007-07-099226 · Cited by 1,234
Self-citationBroz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Van Hove, H., Martens, L., Scheyltjens, I., De Vlaminck, K., Pombo Antunes, A. R., De Prijck, S., Vandamme, N., De Schepper, S., Van Isterdael, G., Scott, C. L., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0393-4 · Cited by 1,074
Self-citationRoberts, E. W., Broz, M. L., Binnewies, M., Headley, M. B., Nelson, A. E., Wolf, D. M., Kaisho, T., Bogunovic, D., Bhardwaj, N., & Krummel, M. F. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.06.003 · Cited by 1,026
A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments
Barry, K. C., Hsu, J., Broz, M. L., Cueto, F. J., Binnewies, M., Combes, A. J., Nelson, A. E., Loo, K., Kumar, R., Rosenblum, M. D., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0085-8 · Cited by 1,021
Mrdjen, D., Pavlovic, A., Hartmann, F. J., Schreiner, B., Utz, S. G., Leung, B. P., Lelios, I., Heppner, F. L., Kipnis, J., Merkler, D., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.01.011 · Cited by 1,010
Darmanis, S., Sloan, S. A., Croote, D., Mignardi, M., Chernikova, S., Samghababi, P., Zhang, Y., Neff, N., Kowarsky, M., Caneda, C., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.10.030 · Cited by 997
Challenges to curing primary brain tumours
Aldape, K., Brindle, K. M., Chesler, L., Chopra, R., Gajjar, A., Gilbert, M. R., Gottardo, N., Gutmann, D. H., Hargrave, D., Holland, E. C., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0177-5 · Cited by 959
Reconstructing and Reprogramming the Tumor-Propagating Potential of Glioblastoma Stem-like Cells
Suvà, M. L., Rheinbay, E., Gillespie, S. M., Patel, A. P., Wakimoto, H., Rabkin, S. D., Riggi, N., Chi, A. S., Cahill, D. P., Nahed, B. V., et al. (2014) · Cell · doi:10.1016/j.cell.2014.02.030 · Cited by 944
Actively personalized vaccination trial for newly diagnosed glioblastoma
Hilf, N., Kuttruff-Coqui, S., Frenzel, K., Bukur, V., Stevanović, S., Gouttefangeas, C., Platten, M., Tabatabai, G., Dutoit, V., van der Burg, S. H., et al. (2019) · Nature · doi:10.1038/s41586-018-0810-y · Cited by 938
Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
Zhao, J., Chen, A. X., Gartrell, R. D., Silverman, A. M., Aparicio, L., Chu, T., Bordbar, D., Shan, D., Samanamud, J., Mahajan, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0349-y · Cited by 903 · cited 2×
“Surpris- ingly, in spite of the immunologically different tumor microenvironment in TCGA subtypes, no asso- ciation was found with ICB responsiveness (Zhao et al., 2019).”
BackgroundImproved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
Liu, J., Blake, S. J., Yong, M. C. R., Harjunpää, H., Ngiow, S. F., Takeda, K., Young, A., O'Donnell, J. S., Allen, S., Smyth, M. J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0577 · Cited by 894
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma
Blank, C. U., Rozeman, E. A., Fanchi, L. F., Sikorska, K., van de Wiel, B., Kvistborg, P., Krijgsman, O., van den Braber, M., Philips, D., Broeks, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0198-0 · Cited by 880
Single-cell profiling identifies myeloid cell subsets with distinct fates during neuroinflammation
Jordão, M. J. C., Sankowski, R., Brendecke, S. M., Sagar, Locatelli, G., Tai, Y.-H., Tay, T. L., Schramm, E., Armbruster, S., Hagemeyer, N., et al. (2019) · Science · doi:10.1126/science.aat7554 · Cited by 843
Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Amaria, R. N., Reddy, S. M., Tawbi, H. A., Davies, M. A., Ross, M. I., Glitza, I. C., Cormier, J. N., Lewis, C., Hwu, W.-J., Hanna, E., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0197-1 · Cited by 835
Recurrent Glioblastoma Treated with Recombinant Poliovirus
Desjardins, A., Gromeier, M., Herndon, J. E., Beaubier, N., Bolognesi, D. P., Friedman, A. H., Friedman, H. S., McSherry, F., Muscat, A. M., Nair, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716435 · Cited by 815
Kioi, M., Vogel, H., Schultz, G., Hoffman, R. M., Harsh, G. R., & Brown, J. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40283 · Cited by 773
Lang, F. F., Conrad, C., Gomez-Manzano, C., Yung, W. K. A., Sawaya, R., Weinberg, J. S., Prabhu, S. S., Rao, G., Fuller, G. N., Aldape, K. D., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.8219 · Cited by 711
Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer
Plitas, G., Konopacki, C., Wu, K., Bos, P. D., Morrow, M., Putintseva, E. V., Chudakov, D. M., & Rudensky, A. Y. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.032 · Cited by 695
De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687
Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma
Chen, Z., Feng, X., Herting, C. J., Garcia, V. A., Nie, K., Pong, W. W., Rasmussen, R., Dwivedi, B., Seby, S., Wolf, S. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2310 · Cited by 675
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Chongsathidkiet, P., Jackson, C., Koyama, S., Loebel, F., Cui, X., Farber, S. H., Woroniecka, K., Elsamadicy, A. A., Dechant, C. A., Kemeny, H. R., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0135-2 · Cited by 668
The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas
Quail, D. F., Bowman, R. L., Akkari, L., Quick, M. L., Schuhmacher, A. J., Huse, J. T., Holland, E. C., Sutton, J. C., & Joyce, J. A. (2016) · Science · doi:10.1126/science.aad3018 · Cited by 666
Müller, S., Kohanbash, G., Liu, S. J., Alvarado, B., Carrera, D., Bhaduri, A., Watchmaker, P. B., Yagnik, G., Di Lullo, E., Malatesta, M., et al. (2017) · Genome Biology · doi:10.1186/s13059-017-1362-4 · Cited by 654
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Woroniecka, K., Chongsathidkiet, P., Rhodin, K., Kemeny, H., Dechant, C., Farber, S. H., Elsamadicy, A. A., Cui, X., Koyama, S., Jackson, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1846 · Cited by 654
Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma
Schalper, K. A., Rodriguez-Ruiz, M. E., Diez-Valle, R., López-Janeiro, A., Porciuncula, A., Idoate, M. A., Inogés, S., de Andrea, C., López-Diaz de Cerio, A., Tejada, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0339-5 · Cited by 642
Chang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
Casazza, A., Laoui, D., Wenes, M., Rizzolio, S., Bassani, N., Mambretti, M., Deschoemaeker, S., Van Ginderachter, J. A., Tamagnone, L., & Mazzone, M. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.007 · Cited by 629
Self-citationUnleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity
Binnewies, M., Mujal, A. M., Pollack, J. L., Combes, A. J., Hardison, E. A., Barry, K. C., Tsui, J., Ruhland, M. K., Kersten, K., Abushawish, M. A., et al. (2019) · Cell · doi:10.1016/j.cell.2019.02.005 · Cited by 629
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627 · cited 1×
“The absence of Nrp1 in Treg leads to their loss of suppressive potential but also to their production of IFNg, which subsequently annihilates the suppressive capacity of neighbouring Nrp1+ Treg in murine tumors (Overacre-Delgoffe et al., 2017).”
Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies
Bowman, R. L., Klemm, F., Akkari, L., Pyonteck, S. M., Sevenich, L., Quail, D. F., Dhara, S., Simpson, K., Gardner, E. E., Iacobuzio-Donahue, C. A., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.052 · Cited by 619
Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis
Delgoffe, G. M., Woo, S.-R., Turnis, M. E., Gravano, D. M., Guy, C., Overacre, A. E., Bettini, M. L., Vogel, P., Finkelstein, D., Bonnevier, J., et al. (2013) · Nature · doi:10.1038/nature12428 · Cited by 587
Rozeman, E. A., Menzies, A. M., van Akkooi, A. C. J., Adhikari, C., Bierman, C., van de Wiel, B. A., Scolyer, R. A., Krijgsman, O., Sikorska, K., Eriksson, H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30151-2 · Cited by 537
Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
Takenaka, M. C., Gabriely, G., Rothhammer, V., Mascanfroni, I. D., Wheeler, M. A., Chao, C.-C., Gutiérrez-Vázquez, C., Kenison, J., Tjon, E. C., Barroso, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0370-y · Cited by 517 · cited 1×
“Also the Aryl Hydrocarbon Receptor (AHR) is indirectly implicated in recruiting monocytes to the tumor environment by driving CCR2 expression, the receptor for the major monocyte chemoat- tractants CCL2 and CCL7 (Takenaka et al., 2019).”
BackgroundWainwright, D. A., Balyasnikova, I. V., Chang, A. L., Ahmed, A. U., Moon, K.-S., Auffinger, B., Tobias, A. L., Han, Y., & Lesniak, M. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2130 · Cited by 472
Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas
Kohanbash, G., Carrera, D. A., Shrivastav, S., Ahn, B. J., Jahan, N., Mazor, T., Chheda, Z. S., Downey, K. M., Watchmaker, P. B., Beppler, C., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci90644 · Cited by 410
Wei, J., Marisetty, A., Schrand, B., Gabrusiewicz, K., Hashimoto, Y., Ott, M., Grami, Z., Kong, L.-Y., Ling, X., Caruso, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci121266 · Cited by 396
Sampson, J. H., Aldape, K. D., Archer, G. E., Coan, A., Desjardins, A., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., et al. (2011) · Neuro-Oncology · doi:10.1093/neuonc/noq157 · Cited by 370
Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma
Chen, P., Zhao, D., Li, J., Liang, X., Li, J., Chang, A., Henry, V. K., Lan, Z., Spring, D. J., Rao, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.003 · Cited by 339
Flores-Toro, J. A., Luo, D., Gopinath, A., Sarkisian, M. R., Campbell, J. J., Charo, I. F., Singh, R., Schall, T. J., Datta, M., Jain, R. K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910856117 · Cited by 334
T-cell Dysfunction in Glioblastoma: Applying a New Framework
Woroniecka, K. I., Rhodin, K. E., Chongsathidkiet, P., Keith, K. A., & Fecci, P. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0047 · Cited by 315
Miska, J., Lee-Chang, C., Rashidi, A., Muroski, M. E., Chang, A. L., Lopez-Rosas, A., Zhang, P., Panek, W. K., Cordero, A., Han, Y., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.029 · Cited by 304
Temozolomide for immunomodulation in the treatment of glioblastoma
Karachi, A., Dastmalchi, F., Mitchell, D. A., & Rahman, M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy072 · Cited by 300
Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
Galstyan, A., Markman, J. L., Shatalova, E. S., Chiechi, A., Korman, A. J., Patil, R., Klymyshyn, D., Tourtellotte, W. G., Israel, L. L., Braubach, O., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11719-3 · Cited by 300
Macrophages of distinct origins contribute to tumor development in the lung
Loyher, P.-L., Hamon, P., Laviron, M., Meghraoui-Kheddar, A., Goncalves, E., Deng, Z., Torstensson, S., Bercovici, N., Baudesson de Chanville, C., Combadière, B., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180534 · Cited by 298
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Batich, K. A., Reap, E. A., Archer, G. E., Sanchez-Perez, L., Nair, S. K., Schmittling, R. J., Norberg, P., Xie, W., Herndon, J. E., Healy, P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2057 · Cited by 295
Laoui, D., Keirsse, J., Morias, Y., Van Overmeire, E., Geeraerts, X., Elkrim, Y., Kiss, M., Bolli, E., Lahmar, Q., Sichien, D., et al. (2016) · Nature Communications · doi:10.1038/ncomms13720 · Cited by 277
Self-citationCorrelation of immune phenotype with IDH mutation in diffuse glioma
Berghoff, A. S., Kiesel, B., Widhalm, G., Wilhelm, D., Rajky, O., Kurscheid, S., Kresl, P., Wöhrer, A., Marosi, C., Hegi, M. E., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox054 · Cited by 254
CCR8+FOXp3+Tregcells as master drivers of immune regulation
Barsheshet, Y., Wildbaum, G., Levy, E., Vitenshtein, A., Akinseye, C., Griggs, J., Lira, S. A., & Karin, N. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1621280114 · Cited by 249
Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma
Hutter, G., Theruvath, J., Graef, C. M., Zhang, M., Schoen, M. K., Manz, E. M., Bennett, M. L., Olson, A., Azad, T. D., Sinha, R., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1721434116 · Cited by 249
Ontogeny of Tumor-Associated Macrophages
Laviron, M., & Boissonnas, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01799 · Cited by 239
Mundt, S., Mrdjen, D., Utz, S. G., Greter, M., Schreiner, B., & Becher, B. (2019) · Science Immunology · doi:10.1126/sciimmunol.aau8380 · Cited by 235
Mrdjen, D., Pavlovic, A., Hartmann, F. J., Schreiner, B., Utz, S. G., Leung, B. P., Lelios, I., Heppner, F. L., Kipnis, J., Merkler, D., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.02.014 · Cited by 220 · cited 1×
“Recent work has shown that various dendritic cell subsets are present in the murine homeostatic brain (Mrdjen et al., 2018; Van Hove et al., 2019), where they are thought be critical for initiating neuroinflammation (Mundt et al., 2019; Jordão et al., 2019).”
Prognostic significance and mechanism of Treg infiltration in human brain tumors
Jacobs, J. F. M., Idema, A. J., Bol, K. F., Grotenhuis, J. A., de Vries, I. J. M., Wesseling, P., & Adema, G. J. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2010.05.020 · Cited by 211
Lamano, J. B., Lamano, J. B., Li, Y. D., DiDomenico, J. D., Choy, W., Veliceasa, D., Oyon, D. E., Fakurnejad, S., Ampie, L., Kesavabhotla, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2402 · Cited by 209
Radiation-Induced Targeted Nanoparticle-Based Gene Delivery for Brain Tumor Therapy
Erel-Akbaba, G., Carvalho, L. A., Tian, T., Zinter, M., Akbaba, H., Obeid, P. J., Chiocca, E. A., Weissleder, R., Kantarci, A. G., & Tannous, B. A. (2019) · ACS Nano · doi:10.1021/acsnano.8b08177 · Cited by 202
Rutledge, W. C., Kong, J., Gao, J., Gutman, D. A., Cooper, L. A. D., Appin, C., Park, Y., Scarpace, L., Mikkelsen, T., Cohen, M. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0551 · Cited by 200
Alban, T. J., Alvarado, A. G., Sorensen, M. D., Bayik, D., Volovetz, J., Serbinowski, E., Mulkearns-Hubert, E. E., Sinyuk, M., Hale, J. S., Onzi, G. R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.122264 · Cited by 197
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
O'Donnell, J. S., Hoefsmit, E. P., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2641 · Cited by 182
Lee-Chang, C., Rashidi, A., Miska, J., Zhang, P., Pituch, K. C., Hou, D., Xiao, T., Fischietti, M., Kang, S. J., Appin, C. L., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0240 · Cited by 171
Wong, E. T., Lok, E., Gautam, S., & Swanson, K. D. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.238 · Cited by 170
Zhang, P., Miska, J., Lee-Chang, C., Rashidi, A., Panek, W. K., An, S., Zannikou, M., Lopez-Rosas, A., Han, Y., Xiao, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1906346116 · Cited by 162
Magnuson, A. M., Kiner, E., Ergün, A., Park, J. S., Asinovski, N., Ortiz-Lopez, A., Kilcoyne, A., Paoluzzi-Tomada, E., Weissleder, R., Mathis, D. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1810580115 · Cited by 158
Raychaudhuri, B., Rayman, P. A., Huang, P., Grabowski, M. M., Hambardzumyan, D., Finke, J. H., & Vogelbaum, M. A. (2015) · Journal of Neuro-Oncology · doi:10.1007/s11060-015-1720-6 · Cited by 148
Tabatabai, G., Frank, B., Möhle, R., Weller, M., & Wick, W. (2006) · Brain · doi:10.1093/brain/awl173 · Cited by 144
Andaloussi, A. E., & Lesniak, M. S. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-006-9314-y · Cited by 142
Wu, A., Maxwell, R., Xia, Y., Cardarelli, P. M., Oyasu, M., Belcaid, Z., Kim, E. S., Hung, A. L., Luksik, A. S., Garzón-Muvdi, T., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03172-5 · Cited by 142
Thymus-derived rather than tumor-induced regulatory T cells predominate in brain tumors
Wainwright, D. A., Sengupta, S., Han, Y., & Lesniak, M. S. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor134 · Cited by 134
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
DiDomenico, J. D., Lamano, J. B., Oyon, D. E., Li, Y., Veliceasa, D., Kaur, G., Ampie, L., Choy, W., Lamano, J. B., & Bloch, O. G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1448329 · Cited by 126
Kumar, S., Sharife, H., Kreisel, T., Mogilevsky, M., Bar-Lev, L., Grunewald, M., Aizenshtein, E., Karni, R., Paldor, I., Shlomi, T., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.04.003 · Cited by 126
FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
Yan, J., Zhao, Q., Gabrusiewicz, K. R., Kong, L.-Y., Xia, X., Wang, J., Ott, M., Xu, J., Davis, R. E., Huo, L., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-08271-x · Cited by 120
Thomas, R. P., Nagpal, S., Iv, M., Soltys, S. G., Bertrand, S., Pelpola, J. S., Ball, R. L., Yang, J., H, V. S. M. P., Chernikova, S. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1421 · Cited by 114
Srivastava, S., Jackson, C., Kim, T., Choi, J. H., & Lim, M. K. (2019) · Cancers · doi:10.3390/cancers11040537 · Cited by 113
Peptide-guided nanoparticles for glioblastoma targeting
Säälik, P., Lingasamy, P., Toome, K., Mastandrea, I., Rousso-Noori, L., Tobi, A., Simón‐Gracia, L., Hunt, H., Paiste, P., Kotamraju, V. R., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.06.018 · Cited by 107
Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation
Davidson, T. B., Lee, A., Hsu, M. S., Sedighim, S., Orpilla, J. R., Treger, J. M., Mastall, M., Roesch, S., Rapp, C., Galvez, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1176 · Cited by 105
Chen, Z., Ross, J., & Hambardzumyan, D. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902366116 · Cited by 105
Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats
Liu, S.-C., Alomran, R., Chernikova, S. B., Lartey, F. M., Stafford, J. H., Jang, T., Merchant, M. J., Zboralski, D., Zöllner, S. K., Kruschinski, A., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/not149 · Cited by 103
Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats
Walters, M. J., Ebsworth, K., Berahovich, R., Penfold, M. E. T., Liu, S.-C., Alomran, R., Kioi, M., Chernikova, S. B., Tseng, D., Mulkearns-Hubert, E. E., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.830 · Cited by 98
Immune Checkpoints and Innovative Therapies in Glioblastoma
Romani, M., Pistillo, M. P., Carosio, R., Morabito, A., & Banelli, B. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00464 · Cited by 97
Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas
Tseng, D., Vasquez-Medrano, D. A., & Brown, J. M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.169 · Cited by 94
Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma
Luoto, S., Hermelo, I., Vuorinen, E. M., Hannus, P., Kesseli, J., Nykter, M., & Granberg, K. J. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3714 · Cited by 89
Next Generation CAR T Cells for the Immunotherapy of High-Grade Glioma
Petersen, C. T., & Krenciute, G. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00069 · Cited by 85
Targeting latency-associated peptide promotes antitumor immunity
Gabriely, G., da Cunha, A. P., Rezende, R. M., Kenyon, B. M., Madi, A., Vandeventer, T., Skillin, N. P., Rubino, S. J., Garo, L. P., Mazzola, M. A., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aaj1738 · Cited by 81
Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
Garzón-Muvdi, T., Theodros, D., Luksik, A. S., Maxwell, R., Kim, E. S., Jackson, C. M., Belcaid, Z., Ganguly, S., Tyler, B., Brem, H., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25061 · Cited by 79
Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma
Park, J., Kim, C. G., Shim, J., Kim, J. H., Lee, H., Lee, J. E., Kim, M. H., Haam, K., Jung, I., Park, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1525243 · Cited by 77
Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma
Poon, C. C., Gordon, P. M. K., Liu, K., Yang, R., Sarkar, S., Mirzaei, R., Ahmad, S. T., Hughes, M. L., Yong, V. W., & Kelly, J. J. (2019) · Oncotarget · doi:10.18632/oncotarget.26863 · Cited by 75
The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma
Yue, Q., Zhang, X., Ye, H.-X., Wang, Y., Du, Z., Yao, Y., & Mao, Y. Q. (2013) · Journal of Neuro-Oncology · doi:10.1007/s11060-013-1314-0 · Cited by 74
Sanchez-Perez, L. A., Choi, B. D., Archer, G. E., Cui, X., Flores, C., Johnson, L. A., Schmittling, R. J., Snyder, D. J., Herndon, J. E., Bigner, D. D., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059082 · Cited by 66
Patel, M. A., Kim, J. E., Theodros, D., Tam, A. J., Velarde, E., Kochel, C. M., Francica, B. J., Nirschl, T. R., Ghasemzadeh, A., Mathios, D., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0132-2 · Cited by 59
The Ontogeny and Microenvironmental Regulation of Tumor-Associated Macrophages
Movahedi, K., & Ginderachter, J. A. V. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2016.6704 · Cited by 58
Self-citationIn-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment
Chitadze, G., Flüh, C., Quabius, E. S., Freitag‐Wolf, S., Peters, C., Lettau, M., Bhat, J., Wesch, D., Oberg, H., Luecke, S., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1358839 · Cited by 55
Regulatory T cells are not a strong predictor of survival for patients with glioblastoma
Thomas, A. A., Fisher, J. L., Rahme, G. J., Hampton, T. H., Baron, U., Olek, S., Schwachula, T., Rhodes, C. H., Gui, J., Tafe, L. J., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou363 · Cited by 52
Lin−CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade
Flores, C. T., Wildes, T. J., Drake, J. A., Moore, G. L., Dean, B. D., Abraham, R. S., & Mitchell, D. A. (2018) · Nature Communications · doi:10.1038/s41467-018-06182-5 · Cited by 52
Checkpoint inhibitors as treatment for malignant gliomas: “A long way to the top”
Simonelli, M., Persico, P., Perrino, M., Zucali, P. A., Navarria, P., Pessina, F., Scorsetti, M., Bello, L., & Santoro, A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.06.016 · Cited by 51
Chandramohan, V., Bao, X., Yu, X., Parker, S., McDowall, C., Yu, Y.-R. A., Healy, P. N., Desjardins, A., Gunn, M. D., Gromeier, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0614-0 · Cited by 46
Anti-GITR therapy promotes immunity against malignant glioma in a murine model
Miska, J. M., Rashidi, A., Chang, A. L., Muroski, M. E., Han, Y., Zhang, L., & Lesniak, M. S. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1912-8 · Cited by 43
Harnessing Radiation Biology to Augment Immunotherapy for Glioblastoma
Rajani, K. R., Carlstrom, L. P., Parney, I. F., Johnson, A. J., Warrington, A. E., & Burns, T. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2018.00656 · Cited by 35
Immunotherapy for glioblastoma: going viral
Iorgulescu, J. B., Reardon, D. A., Chiocca, E. A., & Wu, C. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0142-3 · Cited by 31
Miao, X., Chen, Y., Hao, K., Zheng, M., Chen, B., Li, K., Wang, Y., Zhang, W., Zhang, Y., Mou, X., et al. (2017) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504017x14841698396865 · Cited by 11
Cited by
Pombo Antunes, A. R., Scheyltjens, I., Lodi, F., Messiaen, J., Antoranz, A., Duerinck, J., Kancheva, D., Martens, L., De Vlaminck, K., Van Hove, H., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-020-00789-y · Cited by 704
Self-citationLin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Ravi, V. M., Neidert, N., Will, P., Joseph, K., Maier, J. P., Kückelhaus, J., Vollmer, L., Goeldner, J. M., Behringer, S. P., Scherer, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28523-1 · Cited by 343
Advances in local therapy for glioblastoma — taking the fight to the tumour
van Solinge, T. S., Nieland, L., Chiocca, E. A., & Broekman, M. L. D. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00621-0 · Cited by 334
Sattiraju, A., Kang, S., Giotti, B., Chen, Z., Marallano, V. J., Brusco, C., Ramakrishnan, A., Shen, L., Tsankov, A. M., Hambardzumyan, D., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.017 · Cited by 279
Metadata
- Authors
- Pombo Antunes, A. R., Scheyltjens, I., Duerinck, J., Neyns, B., Movahedi, K., & Van Ginderachter, J. A.
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2020-02-04
- Volume
- 9
- ISSN
- 2050-084X (ISSN-L)
- OpenAlex
- W3005258006
- Cited by
- 272
- References
- 116
- FWCI
- 18.80
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.